MSOS ETF dropped 11% as U.S. cannabis rescheduling was paused, raising 280E uncertainty and concentration risk.
AdvisorShares Pure US Cannabis ETF is reiterated as a Buy despite DEA rescheduling delays. Click to see MSOS valuation, Trulieve Cannabis upside, and key risks.
Cannabis MSO stocks plunged after a DEA judge stayed a marijuana rescheduling hearing. Read more here.
DEA Chief Judge Derek Julius paused the cannabis rescheduling case on Tuesday afternoon.
This is the newest page. Registered accounts read further back.